Ocular allergy treatment

被引：45
作者：
Bielory, Leonard [1 ]
机构：
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA
来源：
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2008年 / 28卷 / 01期
关键词：
D O I：
10.1016/j.iac.2007.12.001
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Nonpharmacologic interventions are commonly used as first-line treatment of ocular allergy and include avoidance, cold compresses, lubrication, and the use of disposable daily contact lenses. Pharmacologic management of ocular allergy has increased exponentially over the past decade. Clinically available agents are being expanded to specifically address the various signs and symptoms of inflammation associated with ocular allergy. Immunotherapy has been shown to decrease the sensitivity of the eye 10 to 100 fold and may have an effect for several years after halting of immunotherapy.
引用
收藏
页码：189 / 224
页数：36
相关论文
共 221 条
[1]  
ABELSON MB, 1981, ARCH OPHTHALMOL-CHIC, V99, P302
[2]   Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model [J].
Abelson, MB .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (03) :211-218
[3]   Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis [J].
Abelson, MB ;
Gomes, P ;
Crampton, HJ ;
Schiffman, RM ;
Bradford, RR ;
Whitcup, SM .
CLINICAL THERAPEUTICS, 2004, 26 (01) :35-47
[4]   Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies [J].
Abelson, MB ;
Berdy, GJ ;
Mundorf, T ;
Amdahl, LD ;
Graves, AL .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2002, 18 (05) :475-488
[5]  
ABELSON MB, 1984, OPHTHALMOLOGY, V91, P1364
[6]   EFFECTS OF VASOCON-A IN THE ALLERGEN CHALLENGE MODEL OF ACUTE ALLERGIC CONJUNCTIVITIS [J].
ABELSON, MB ;
PARADIS, A ;
GEORGE, MA ;
SMITH, LM ;
MAGUIRE, L ;
BURNS, R .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (04) :520-524
[7]   An evaluation of onset and duration of action of Patanol® (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin® (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model [J].
Abelson, MB ;
Welch, DL .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 :60-63
[8]   Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity [J].
Abelson, MB ;
Spitalny, L .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 125 (06) :797-804
[9]   The added benefit of local patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model [J].
Abelson, MB ;
Lanier, RQ .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 1999, 77 :53-56
[10]   Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate [J].
Aguilar, AJ .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 :52-55
12345678910